Výsledky vyhledávání - "Kristen A. Hamanishi"

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa

Autor: Kelley C. Gordon, P. Richard Harrigan, Chanson J. Brumme, Maritsa Scoulos-Hanson, Raquel V. Viana, Urvi M. Parikh, Carole L. Wallis, Kristen A. Hamanishi, Kerri J. Penrose, John W. Mellors

Publikováno v: Antiviral Chemistry & Chemotherapy
Antiviral Chemistry & Chemotherapy, Vol 26 (2018)

Background Rilpivirine (TMC278LA) is a promising drug for pre-exposure prophylaxis of HIV-1 because of its sub-nanomolar potency and long-acting formulation; however, increasing transmission of non-nucleoside reverse transcriptase inhibitor-resistant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aecad33d40309373e591f68b18b148fb
http://europepmc.org/articles/PMC5890541

Zobrazit plný text záznamu

Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa

Autor: P. Richard Harrigan, Chanson J. Brumme, Kristen A. Hamanishi, Urvi M. Parikh, Raquel V. Viana, Carole L. Wallis, Kerri J. Penrose, John W. Mellors, Kelley C. Gordon

Publikováno v: Antimicrobial Agents and Chemotherapy. 61

A vaginal ring containing dapivirine (DPV) has shown moderate protective efficacy against HIV-1 acquisition, but the activity of DPV against efavirenz (EFV)- and nevirapine (NVP)-resistant viruses that could be transmitted is not well defined. We inv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df1d1cea8f459bccf33b91b82a44ebfc
https://doi.org/10.1128/aac.01805-16

Zobrazit plný text záznamu

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)

Autor: Marta Boffito, Kristen A. Hamanishi, Kerri J. Penrose, Laura Else, David Back, Akil Jackson, John W. Mellors, Urvi M. Parikh

Publikováno v: The Journal of infectious diseases. 213(6)

The injectable long-acting formulation of rilpivirine (TMC278LA) is a promising preexposure prophylaxis (PrEP) candidate for prevention of human immunodeficiency virus type 1 (HIV-1) infection. We evaluated HIV-1 in plasma obtained from an unexpected

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93ebdc47b0086709e55e4629d8e0044c
https://pubmed.ncbi.nlm.nih.gov/26563240

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání